[The possibilities for improving the serological diagnosis of active tuberculosis by using new mycobacterial antigens and immunoblot and ELISA technics].

The study concerns 264 cases among which: 119 active lung tb. eliminating and 11 cases not-eliminating M. Tuberculosis; 17 cases of extrarespiratory tb.

[The possibilities of improving the serological diagnosis of active tuberculosis by using the technics of immunofluorescence and ELISA].

A group of 188 adult subjects has been studied as follows: 119 cases of pulmonary tb confirmed by smear and/or culture; 44 cases with other chronic lung diseases; 25 healthy persons. The following serological tests have been performed: immunofluorescence indirect test (FA) using mycobacterial total antigen; ELISA test using two antigens: PPD and a freeze dried crude sonicated extract from H37Rv strain (antigen "Prague"). The results show: sensitivity 77% for FA and 71% for ELISA; specificity 81% for FA and 86% for ELISA.

[Results of continuous treatment (3 years) with disodium cromoglycate of patients with bronchial asthma and spastic bronchitis].

A group including 36 patients with bronchial asthma and 8 with spastic bronchitis have been treated with disodium cromoglycate for a period of 3 years starting with July 1-st, 1978. Eight of these patients also had allergic rhinitis, and in these ones administration of the treatment was also made by nasal application. Partial results have been published after 3 and 18 months of treatment.

[Preliminary results of the use of a new derivative of rifamycin SV in the treatment of sarcoidosis].

Seven patients with advanced forms of mediastino-pulmonary sarcoidosis (involvement of the pulmonary parenchyma, and restrictive respiratory syndrome), confirmed by histopathologic investigation, have been treated with a new SV-rifamycin derivative, 1246-EH, or "Reprimum" without any other association. Reprimun was given in daily doses of 10 mg/kg of body weight for a period of two weeks, then, for another 4-5 weeks, the drugs was given intermittently in doses of 15 mg/kg of body weight twice weekly. Between two cycles of therapy a period of 14 days was free of drug administration.

[Immunological aspects of adverse reactions during treatment with rifampicin].

It has already been established that during the treatment with rifampicin severe adverse reactions may occur, especially mediated by immune mechanisms. The most severe are those followed by renal failure. This type of reactions usually occur in patients that have undergone previous long treatments with the drug (RMP), given intermittently, twice a week, who, after an intermission, take up again the treatment with rifampicin.

[Disodium cromoglycate treatment of bronchial asthma and spastic bronchitis (preliminiary results)].

After a short review of the mode of action of sodium chromoglycate, the results are presented, of the treatment carried out over a three months period in a group of 31 patients of which 23 had bronchial asthma and 8 had spastic bronchitis. In 19 cases the doses of steroids that the patients were receiving were either diminished or supressed, in 14 cases the doses of broncho-dilating drugs were diminished or supressed and in 15 cases the results of the respiratory function tests were improved or much improved. A synthetic evaluation of the clinical and laboratory results showed that in 3/4 of the cases (74.

[Clinical studies of the role of the fluorescent circulating antibody test in the diagnosis of active tuberculosis].

The value was studied, of the test of circulating fluorescent antibodies against M. tuberculosis in establishing the diagnosis of active tuberculosis in 610 patients classified in 4 groups: 1. active tuberculosis bacteriologically confirmed; 2.

[Study of adverse reactions in pulmonary tuberculosis patients treated with rifampicin].

The present study concerns the clinical appraisal of adverse reactions reported in the course of Rifampicin (RMP) treatment, reactions which have given rise to conflicting reports. The lot studied included 243 cases of pulmonary tuberculosis of which 57 were treated according to the 7/7 regime (600 mg RMP), 152 according to the 2/7 regimen (900-1200 mg RMP) and 34 according to the 7/7 followed by the 2/7 regimen. Tolerance to RMP was followed up by a series of adequate tests and close clinical surveillance.